CL2018001804A1 - Uso de la carrimicina en la infección por micobacterium tuberculosis resistente - Google Patents

Uso de la carrimicina en la infección por micobacterium tuberculosis resistente

Info

Publication number
CL2018001804A1
CL2018001804A1 CL2018001804A CL2018001804A CL2018001804A1 CL 2018001804 A1 CL2018001804 A1 CL 2018001804A1 CL 2018001804 A CL2018001804 A CL 2018001804A CL 2018001804 A CL2018001804 A CL 2018001804A CL 2018001804 A1 CL2018001804 A1 CL 2018001804A1
Authority
CL
Chile
Prior art keywords
resistant
carrimycin
carrimicin
mycobacterium tuberculosis
tuberculosis infection
Prior art date
Application number
CL2018001804A
Other languages
English (en)
Inventor
Yiguang Wang
Yang Jiang
Xiaofeng Zhao
Weiqing He
Original Assignee
Shenyang Fuyang Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Fuyang Pharmaceutical Tech Co Ltd filed Critical Shenyang Fuyang Pharmaceutical Tech Co Ltd
Publication of CL2018001804A1 publication Critical patent/CL2018001804A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

EL USO DE LA CARRIMICINA EN LA INFECCIÓN DEBIDA AL MICOBACTERIUM TUBERCULOSIS RESISTENTE COMPRENDE LAS SIGUIENTES ETAPAS: MEDIR LA ACTIVIDAD DE LA CARRIMICINA EN EL MICOBACTERIUM TUBERCULOSIS RESISTENTE MEDIANTE LA ADOPCIÓN DE UN MÉTODO DE CONCENTRACIÓN ABSOLUTA A TRAVÉS DE LA TOMA, COMO CONTROLES, DE ANTITUBERCULÓSICOS DE PRIMERA LÍNEA, COMO LA ISONIAZIDA Y LA RIFAMPICINA. EL RESULTADO INDICA QUE LA CARRIMICINA TIENE UNA ACTIVIDAD OBVIAMENTE SUPERIOR CONTRA EL MICOBACTERIUM TUBERCULOSIS SEPARADO CLÍNICAMENTE, LO QUE INCLUYE BACTERIAS RESISTENTES A FÁRMACOS COMPARADAS CON AQUELLAS DE LOS FÁRMACOS CONTROL DE PRIMERA LÍNEA, ES DECIR, LA ISONIAZIDA Y LA RIFAMPICINA, Y EL USO DE LA CARRIMICINA EN LA FABRICACIÓN DE FÁRMACOS PARA TRATAR LAS ENFERMEDADES INFECCIOSAS DEBIDAS AL BACILO TUBERCULOSO.
CL2018001804A 2015-12-31 2018-06-29 Uso de la carrimicina en la infección por micobacterium tuberculosis resistente CL2018001804A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201511030787.7A CN105497053B (zh) 2015-12-31 2015-12-31 可利霉素在抗结核分枝杆菌感染中的应用

Publications (1)

Publication Number Publication Date
CL2018001804A1 true CL2018001804A1 (es) 2018-09-28

Family

ID=55705614

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001804A CL2018001804A1 (es) 2015-12-31 2018-06-29 Uso de la carrimicina en la infección por micobacterium tuberculosis resistente

Country Status (20)

Country Link
US (1) US11000708B2 (es)
EP (1) EP3384915B1 (es)
JP (1) JP6770584B2 (es)
KR (1) KR20180098624A (es)
CN (1) CN105497053B (es)
AU (1) AU2016382584B2 (es)
BR (1) BR112018013327A2 (es)
CA (1) CA3010020A1 (es)
CL (1) CL2018001804A1 (es)
CO (1) CO2018007133A2 (es)
DK (1) DK3384915T3 (es)
ES (1) ES2785644T3 (es)
MY (1) MY191800A (es)
PE (1) PE20190210A1 (es)
PH (1) PH12018501394A1 (es)
PL (1) PL3384915T3 (es)
RU (1) RU2733382C2 (es)
UA (1) UA121159C2 (es)
WO (1) WO2017114095A1 (es)
ZA (1) ZA201804398B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105497053B (zh) 2015-12-31 2018-02-13 沈阳福洋医药科技有限公司 可利霉素在抗结核分枝杆菌感染中的应用
AU2018247555B2 (en) * 2017-04-06 2024-04-18 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin and pharmaceutically acceptable salt thereof for manufacture of medicament for treatment and/or prevention of tumors
CN110384710B (zh) * 2018-04-17 2023-01-10 沈阳福洋医药科技有限公司 一种用于预防和/或治疗疼痛的药物、组合产品及其应用
CN110384802B (zh) * 2018-04-17 2021-09-17 沈阳福洋医药科技有限公司 一种用于预防和/或治疗发热的药物、组合产品及其应用
WO2021219112A1 (zh) * 2020-04-30 2021-11-04 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗脓毒症疾病药物中的应用
CN113577086B (zh) * 2020-04-30 2023-05-02 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用
WO2022119899A1 (en) * 2020-12-02 2022-06-09 Shionogi & Co., Ltd. A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2126108B1 (es) * 1971-02-25 1974-08-02 Rhone Poulenc Sa
US7098219B2 (en) * 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
CN1237976C (zh) * 2003-12-23 2006-01-25 沈阳同联集团有限公司 必特螺旋霉素及其在抗感染性疾病中的应用
US20080161249A1 (en) * 2004-11-17 2008-07-03 Smithkline Beecham Corporation Use of Novel Antibacterial Compounds
DE102005058345A1 (de) * 2005-12-06 2007-06-14 Kern, Andreas, Dr. med. Verwendung eines oral einzunehmenden Antibiotikums
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy
US9089586B2 (en) * 2010-05-25 2015-07-28 Shenyang Tonglian Group Co., Ltd. Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof
US8778896B2 (en) * 2010-05-25 2014-07-15 Shenyang Tonglian Group Co., Ltd. Levoisovalerylspiramycin I, II or III, preparations, preparation methods and uses thereof
JP6116206B2 (ja) 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
CN103142520B (zh) * 2013-03-15 2015-04-01 沈阳同联集团有限公司 一种可利霉素片及其制备方法
CN105497053B (zh) * 2015-12-31 2018-02-13 沈阳福洋医药科技有限公司 可利霉素在抗结核分枝杆菌感染中的应用

Also Published As

Publication number Publication date
CA3010020A1 (en) 2017-07-06
BR112018013327A2 (pt) 2018-12-04
RU2018125622A3 (es) 2020-03-26
KR20180098624A (ko) 2018-09-04
CN105497053A (zh) 2016-04-20
ES2785644T3 (es) 2020-10-07
CO2018007133A2 (es) 2018-07-19
JP6770584B2 (ja) 2020-10-14
WO2017114095A1 (zh) 2017-07-06
JP2019501220A (ja) 2019-01-17
PH12018501394A1 (en) 2019-02-27
EP3384915B1 (en) 2020-02-19
EP3384915A1 (en) 2018-10-10
CN105497053B (zh) 2018-02-13
RU2733382C2 (ru) 2020-10-01
RU2018125622A (ru) 2020-01-31
PL3384915T3 (pl) 2020-09-07
US20190001160A1 (en) 2019-01-03
EP3384915A4 (en) 2018-12-19
AU2016382584A1 (en) 2018-07-26
US11000708B2 (en) 2021-05-11
ZA201804398B (en) 2019-09-25
MY191800A (en) 2022-07-15
AU2016382584B2 (en) 2022-01-06
PE20190210A1 (es) 2019-02-07
DK3384915T3 (en) 2020-05-04
UA121159C2 (uk) 2020-04-10

Similar Documents

Publication Publication Date Title
CL2018001804A1 (es) Uso de la carrimicina en la infección por micobacterium tuberculosis resistente
CL2017003404A1 (es) Compuestos antibacterianos
CL2017003033A1 (es) Dispositivo de monitorización para la aplicación de un fármaco con una pluma de fármaco, con registro, comunicación y alarmas.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2017000855A1 (es) Inmunomoduladores
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
CR20150519A (es) Compuestos de 1, 3-oxazin-2-amina fusionados con cilopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
UY35240A (es) Compuestos y métodos para la modulación de quinasas y sus indicaciones
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
PE20180260A1 (es) Metodos y kits para tratar la depresion
CL2016002971A1 (es) Combinación.
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
CY1122185T1 (el) Ιατρικη χρηση ενωσεων αρτεμισινινης και αγωνιστων γεφυρινης
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR089993A1 (es) Macrociclos peptidomimeticos
UY34851A (es) Inhibidores macrocíclicos de virus flaviviridae
SV2016005301A (es) Nuevos compuestos macrocíclicos
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
UY36938A (es) Nuevos compuestos macrocíclicos modificados
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo